These four large cap top pick stocks would make stellar additions to growth stock portfolios. All pay dependable dividends and are good candidates to continue raising those dividends in years to come.
If there is one cure or one treatment that could be the proverbial Holy Grail for a pharmaceutical or biotech company, it would be in a successful treatment of Alzheimer's disease.
The top analyst upgrades, downgrades and other research calls from Tuesday include Altria, Apple, Discovery, DowDuPont, JPMorgan, Red Hat and T-Mobile.
Companies included on the S&P 500 index bought back more than $500 billion in stock last year and have bought back more than $4 trillion in shares since 2008.
The top analyst upgrades, downgrades and other research calls from Monday include CenterPoint Energy, NetApp, NiSource, Nvidia, Orbital ATK and Weyerhaeuser.
Big opportunities in emerging health care companies often come with very bumpy rides. There is also the risk, of course, that there are no assurances that the potential promise and upside will…
Jon C. Ogg Credit Suisse provided its outlook for several large-cap pharmaceutical stocks Monday morning. The analyst has three top picks to consider.
JPMorgan has made the case that the best place for investors to look when considering large cap drug stocks is companies that have strong new product cycles already in motion.
A good rule of thumb for investors looking to add to portfolios now is to seek growth stocks with upside potential that also pay good dividends, and importantly, continue to grow those…
Friday’s top analyst upgrades, downgrades and initiations include Costco, Domino's Pizza, Fortinet, Verizon Communications and Yum Brands.
One thing that could help this market would be either a solid sell-off or a long sideways move. Either way, gains need to be consolidated, so it’s likely the sellers will continue…
24/7 Wall St. has put together a preview of some of the major companies reporting their quarterly results on Wednesday.
None of these stocks is a momentum giant, but they all offer investors solid value in a market that not only could use a breather, but really could use a healthy correction.
2016 was hard for biotech stocks, some more than others. These three present a buy low opportunity.
Consumer staples represented the largest aggregate purchases among the top 50 hedge funds during the third quarter of 2016.
